Intraneuronal Aβ accumulation induces hippocampal neuron hyperexcitability through A-type K+ current inhibition mediated by activation of caspases and GSK-3
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Amyloid β-protein (Aβ) pathologies have been linked to dysfunction of excitability in neurons of the hippocampal circuit, but the molecular mechanisms underlying this process are still poorly understood. Here, we applied whole-cell patch-clamp electrophysiology to primary hippocampal neurons and show that intracellular Aβ42 delivery leads to increased spike discharge and action potential broadening through downregulation of A-type K+ currents. Pharmacologic studies showed that caspases and glycogen synthase kinase 3 (GSK-3) activation are required for these Aβ42-induced effects. Extracellular perfusion and subsequent internalization of Aβ42 increase spike discharge and promote GSK-3-dependent phosphorylation of the Kv4.2 α-subunit, a molecular determinant of A-type K+ currents, at Ser-616. In acute hippocampal slices derived from an adult triple-transgenic Alzheimer’s mouse model, characterized by endogenous intracellular accumulation of Aβ42, CA1 pyramidal neurons exhibit hyperexcitability accompanied by increased phosphorylation of Kv4.2 at Ser-616. Collectively, these data suggest that intraneuronal Aβ42 accumulation leads to an intracellular cascade culminating into caspases activation and GSK-3-dependent phosphorylation of Kv4.2 channels. These findings provide new insights into the toxic mechanisms triggered by intracellular Aβ42 and offer potentially new therapeutic targets for Alzheimer’s disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…transgenic mouse models (Guzman et al., 2014; Youmans et al., 2012; for review see; LaFerla et al., 2007), leading to the overall hypothesis of iAβ accumulation as an early triggering event in the AD progression preceding senile plaques (Kuo et al., 2001; LaFerla et al., 2007; Oakley et al., 2006).”
BackgroundPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 1×
“…(Nicholson, 1999) have been implicated in hippocampal synaptic plasticity (Jo et al., 2011; Li and Sheng, 2012), have been associated with AD and can be activated on Aβ exposure (Allen et al., 2001; Cho and Johnson, 2004; Chong et al., 2006; Heneka et al., 2013; Jo et al., 2011; Mattson, 2004).”
BackgroundJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · cited 2×
“%) is the 42-residues variant (Aβ42), a species that because of its high hydrophobicity has been considered more prone to fibril formation and neurotoxicity than the Aβ40 (Jarrett et al., 1993).”
BackgroundIntracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“Furthermore, the soluble Aβ42 complex associated with apolipoprotein E promotes Aβ internalization (Gylys et al., 2003; Kim et al., 2009; Kuszczyk et al., 2013).”
BackgroundPalop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653 · cited 3×
“…increased excitability of hippocampal neurons, leading to hypersynchronous network activity and higher risk for seizures (Born et al., 2014; Brown et al., 2011; Busche et al., 2012; Davis et al., 2014; Del Vecchio et al., 2004; Minkeviciene et al., 2009; Palop et al., 2007; Putcha et al., 2011).”
BackgroundGSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
Molecular Diversity of K+ Channels
COETZEE, W. A., AMARILLO, Y., CHIU, J., CHOW, A., LAU, D., McCORMACK, T., MORENA, H., NADAL, M. S., OZAITA, A., POUNTNEY, D., et al. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11293.x · Cited by 1,095 · cited 1×
“2 subunit is prominently expressed in CA1 hippocampal neurons, where it has been proposed to mediate sub-threshold and fast inactivating A-type K+ currents (Coetzee et al., 1999; Kim and Hoffman, 2012; Lin et al., 2011; Varga et al., 2000).”
BackgroundNeurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 2×
“It is believed, indeed, that disruption in synaptic structure and function induced by Aβ42 is one of the underlying mechanisms leading to the aberrant neuronal processing and network dysfunction that characterize AD cognitive impairment and memory loss (Mucke and Selkoe, 2012).”
BackgroundIntraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript immunoreactivity of intracellular Aβ42 (iAβ42) has been identified in neurons of the hippocampus and entorhinal cortex (Gouras et al., 2000; Mori et al., 2002), the 2 main brain regions affected in early AD pathology.”
BackgroundBusche, M. A., Chen, X., Henning, H. A., Reichwald, J., Staufenbiel, M., Sakmann, B., & Konnerth, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206171109 · Cited by 715
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 1×
“Hyperphosphorylation of tau and Aβ production in AD have been linked to GSK-3 dysfunction (DaRocha-Souto et al., 2012; Noble et al., 2005; Phiel et al., 2003; Neurobiol Aging.”
BackgroundEpilepsy and Cognitive Impairments in Alzheimer Disease
Palop, J. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.15 · Cited by 684 · cited 1×
“To this regard, it should be considered that although seizures are increased in the AD patients, overall epilepsy is not a common feature in AD (Amatniek et al., 2006; Palop and Mucke, 2009).”
BackgroundAmyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489 · cited 1×
“This may reflect the inability of 6E10 antibody to neutralize all internalized Aβ42 in agreement with previous studies (Klyubin et al., 2005; Tampellini et al., 2007).”
ResultSynapses and Alzheimer's Disease
Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436 · cited 2×
“…studies have reported toxic activity of Aβ42 oligomers on synaptic function and activity-dependent plasticity in the hippocampus and cerebral cortex building the notion that AD is a synaptopathy (Crimins et al., 2013; Klyubin et al., 2012; Selkoe, 2002; Shankar et al., 2008; Sheng et al., 2012).”
BackgroundMicrotubule-associated protein tau is essential for long-term depression in the hippocampus
Kimura, T., Whitcomb, D. J., Jo, J., Regan, P., Piers, T., Heo, S., Brown, C., Hashikawa, T., Murayama, M., Seok, H., et al. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0144 · Cited by 307
Aβ1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β
Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2785 · Cited by 305 · cited 9×
“GSK-3β activity is normally suppressed by its Nterminal phosphorylation at Ser-9 induced by protein kinase type 1 (Akt-1) (Emamian et al., 2004; Jo et al., 2011).”
BackgroundResultInfluentialWhite, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Pooler et al., 2012; White et al., 2006; Kimura et al., 2013).”
BackgroundIntraneuronal Aβ42 accumulation in Down syndrome brain: Original Articles
Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., & Lemere, C. A. (2002) · Amyloid · doi:10.3109/13506120208995241 · Cited by 255 · cited 2×
“immunoreactivity of intracellular Aβ42 (iAβ42) has been identified in neurons of the hippocampus and entorhinal cortex (Gouras et al., 2000; Mori et al., 2002), the 2 main brain regions affected in early AD pathology.”
BackgroundCaspase-3 activation as a bifurcation point between plasticity and cell death
Snigdha, S., Smith, E. D., Prieto, G. A., & Cotman, C. W. (2012) · Neuroscience Bulletin · doi:10.1007/s12264-012-1057-5 · Cited by 227 · cited 1×
“Recently, the role caspase-3, specifically, has been identified in nonapoptotic processes in the central nervous system, such as synaptic plasticity, spine structure, and memory formation (D’Amelio and Rossini, 2012; Snigdha et al., 2012).”
BackgroundDaRocha-Souto, B., Coma, M., Pérez-Nievas, B. G., Scotton, T. C., Siao, M., Sánchez-Ferrer, P., Hashimoto, T., Fan, Z., Hudry, E., Barroeta, I., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.002 · Cited by 180 · cited 2×
“In double transgenic APP/tau mice, GSK-3 inhibition ameliorates plaque-related neuritic changes, suggesting a role of this kinase in Aβ-induced pathology (DaRocha-Souto et al., 2012).”
BackgroundBorn, H. A., Kim, J.-Y., Savjani, R. R., Das, P., Dabaghian, Y. A., Guo, Q., Yoo, J. W., Schuler, D. R., Cirrito, J. R., Zheng, H., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5171-13.2014 · Cited by 178 · cited 2×
“In animal models that overexpress Aβ, spontaneous network hyperexcitability has been documented (Born et al., 2014; Davis et al., 2014; Marcantoni et al., 2014; Minkeviciene et al., 2009; Palop et al., 2007).”
BackgroundIntraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody
Youmans, K. L., Tai, L. M., Kanekiyo, T., Stine Jr, W. B., Michon, S.-C., Nwabuisi-Heath, E., Manelli, A. M., Fu, Y., Riordan, S., Eimer, W. A., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-8 · Cited by 164 · cited 2×
“These findings have been corroborated by results from transgenic mouse models (Guzman et al., 2014; Youmans et al., 2012; for review see; LaFerla et al., 2007), leading to the overall hypothesis of iAβ accumulation as an early triggering event in the AD progression preceding senile plaques (Kuo et…”
ResultCo-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses
Takahashi, R. H., Capetillo-Zarate, E., Lin, M. T., Milner, T. A., & Gouras, G. K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.021 · Cited by 150 · cited 2×
“Converging evidence highlights a critical role of iAβ in AD pathology (Gouras et al., 2012; Ripoli et al., 2014; Takahashi et al., 2014; Zepa et al., 2011) and in its symptoms (Steinerman et al.”
BackgroundDynamic association of tau with neuronal membranes is regulated by phosphorylation
Pooler, A. M., Usardi, A., Evans, C. J., Philpott, K. L., Noble, W., & Hanger, D. P. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.005 · Cited by 148 · cited 2×
“Hyperphosphorylation of tau and Ab production in AD have been linked to GSK-3 dysfunction (DaRocha-Souto et al., 2012; Noble et al., 2005; Phiel et al., 2003; Pooler et al., 2012; White et al., 2006; Kimura et al., 2013).”
BackgroundTampellini, D., Magrané, J., Takahashi, R. H., Li, F., Lin, M. T., Almeida, C. G., & Gouras, G. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700373200 · Cited by 118 · cited 3×
“The monoclonal antibody 6E10 recognizes the N-terminus of human Aβ42, and efficiently immunoprecipitates oligomeric and monomeric Aβ42 present in conditioned medium (Tampellini et al., 2007).”
BackgroundMethodResultClementi, M. E., Pezzotti, M., Orsini, F., Sampaolese, B., Mezzogori, D., Grassi, C., Giardina, B., & Misiti, F. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.137 · Cited by 105
Self-citationDistinct Pools of β-Amyloid in Alzheimer Disease–Affected Brain: A Clinicopathologic Study
Steinerman, J. R., Irizarry, M., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B., & Stern, Y. (2008) · Archives of Neurology · doi:10.1001/archneur.65.7.906 · Cited by 104 · cited 1×
“Converging evidence highlights a critical role of iAβ in AD pathology (Gouras et al., 2012; Ripoli et al., 2014; Takahashi et al., 2014; Zepa et al., 2011) and in its symptoms (Steinerman et al., 2008).”
BackgroundKuszczyk, M. A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A. A., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.034 · Cited by 97 · cited 1×
“Furthermore, the soluble Aβ42 complex associated with apolipoprotein E promotes Aβ internalization (Gylys et al., 2003; Kim et al., 2009; Kuszczyk et al., 2013).”
BackgroundKuo, Y.-M., Beach, T. G., Sue, L. I., Scott, S., Layne, K. J., Kokjohn, T. A., Kalback, W. M., Luehrs, D. C., Vishnivetskaya, T. A., Abramowski, D., et al. (2001) · Molecular Medicine · doi:10.1007/bf03401867 · Cited by 90 · cited 1×
“…transgenic mouse models (Guzman et al., 2014; Youmans et al., 2012; for review see; LaFerla et al., 2007), leading to the overall hypothesis of iAβ accumulation as an early triggering event in the AD progression preceding senile plaques (Kuo et al., 2001; LaFerla et al., 2007; Oakley et al., 2006).”
BackgroundCurcio, L., Podda, M. V., Leone, L., Piacentini, R., Mastrodonato, A., Cappelletti, P., Sacchi, S., Pollegioni, L., Grassi, C., & D’Ascenzo, M. (2013) · Brain · doi:10.1093/brain/awt036 · Cited by 79
Self-citationKapfhamer, D., Berger, K. H., Hopf, F. W., Seif, T., Kharazia, V., Bonci, A., & Heberlein, U. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1292-10.2010 · Cited by 71 · cited 1×
“Thus, by decreasing the level of tonic GSK-3 inhibition eAβ42 might markedly increase the GSK-3 active pool with consequences for neuronal excitability (Kapfhamer et al., 2010; Wildburger and Laezza, 2012).”
BackgroundGouras, G. K., Willén, K., & Tampellini, D. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.06.004 · Cited by 39 · cited 2×
“Converging evidence highlights a critical role of iAβ in AD pathology (Gouras et al., 2012; Ripoli et al., 2014; Takahashi et al., 2014; Zepa et al., 2011) and in its symptoms (Steinerman et al.”
BackgroundZepa, L., Frenkel, M., Belinson, H., Kariv-Inbal, Z., Kayed, R., Masliah, E., & Michaelson, D. M. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/792070 · Cited by 23
Cited by
Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313
Self-citationWhat Happens with the Circuit in Alzheimer's Disease in Mice and Humans?
Zott, B., Busche, M. A., Sperling, R. A., & Konnerth, A. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061725 · Cited by 221
LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent
Puzzo, D., Piacentini, R., Fá, M., Gulisano, W., Li Puma, D. D., Staniszewski, A., Zhang, H., Tropea, M. R., Cocco, S., Palmeri, A., et al. (2017) · eLife · doi:10.7554/elife.26991 · Cited by 172
Self-citationKazim, S. F., Chuang, S.-C., Zhao, W., Wong, R. K. S., Bianchi, R., & Iqbal, K. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00071 · Cited by 109
“GraphPad Prism 7.0 (GraphPad Software Inc., LaJolla, CA, USA) was used for statistical analysis, with p < 0.05 considered as statistical significance level.”
BackgroundMethodInfluentialControl of neuronal excitability by GSK-3beta: epilepsy and beyond.
Jaworski, T. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118745 · Cited by 43
Metadata
- Authors
- Scala, F., Fusco, S., Ripoli, C., Piacentini, R., Li Puma, D. D., Spinelli, M., Laezza, F., Grassi, C., & D'Ascenzo, M.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 36
- Issue
- 2
- Pages
- 886-900
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2029371901
- Cited by
- 94
- References
- 38
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.